DrugPatentWatch Database Preview
Details for Patent: 7,767,678
» See Plans and Pricing
Which drugs does patent 7,767,678 protect, and when does it expire?
Patent 7,767,678 protects BOSULIF and is included in one NDA.
This patent has twenty-six patent family members in twenty-six countries.
Summary for Patent: 7,767,678
| Title: | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-pipera- zinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
| Abstract: | This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-pipera- zinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2.theta. angles (.degree.) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109.degree. C. to about 115.degree. C. |
| Inventor(s): | Tesconi; Marc Sadler (Monroe, NY), Feigelson; Gregg (Chester, NY), Strong; Henry (Somerset, NJ), Wen; Hong (Westfield, NJ) |
| Assignee: | Wyeth LLC (Madison, NJ) |
| Application Number: | 11/478,216 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,767,678 |
|
Patent Claim Types: see list of patent claims | Compound; Use; Composition; |
Drugs Protected by US Patent 7,767,678
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-001 | Sep 4, 2012 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,767,678
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 054505 | Start Trial | |||
| Australia | 2006266045 | Start Trial | |||
| Brazil | PI0613574 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
